Research To Practice | Oncology Videos

Featuring perspectives from Dr Edward B Garon, Dr John V Heymach, Dr Corey J Langer, Dr Ticiana Leal, Dr David R Spigel and Dr Helena Yu, including the following topics: Incorporation of Immunotherapeutic Strategies into the Management of Nonmetastatic Non-Small Cell Lung Cancer (NSCLC) Introduction (0:00) Strategies to cope with platinum shortages (3:11) Selection of appropriate candidates for neoadjuvant chemoimmunotherapy (5:51) Current clinical role of adjuvant anti-PD-1/PD-L1 antibodies (11:03) Patient selection for and practical implementation of consolidation durvalumab (15:40) Faculty presentation: Dr Heymach (18:05) Contemporary Treatment for Localized or Metastatic NSCLC with an EGFR Mutation Adjuvant osimertinib for EGFR mutation-positive localized NSCLC (29:45) Potential implications of FLAURA2 (35:43) Promising investigational strategies for progressive EGFR-mutant disease (38:15) Sequencing of therapies for metastatic NSCLC with EGFR exon 20 insertion mutations (42:01) Faculty presentation: Dr Yu (46:07) Research Advances Shaping the Current and Future Treatment of Metastatic NSCLC with ALK Rearrangements, ROS1 Rearrangements or RET Fusions Selection of first- and later-line treatment for ALK-rearranged NSCLC (54:36) Role of RET-targeted therapy in current clinical practice (56:53) Selection of therapy for ROS1-positive NSCLC, including for patients with CNS involvement (59:30) Faculty presentation: Dr Langer (1:01:25) Targeting MET, HER2 and KRAS Alterations in NSCLC Current clinical role of trastuzumab deruxtecan in NSCLC (1:16:14) Therapeutic sequencing for NSCLC with KRAS G12C mutations (1:20:41) Management of MET exon 14 mutation-positive NSCLC (1:24:33) Faculty presentation: Dr Spigel (1:29:36) Current Management of Metastatic NSCLC without a Targetable Tumor Mutation Anti-PD-1/PD-L1 antibodies for patients for whom biomarker testing is pending (1:38:48) Selection of first-line therapy for newly diagnosed metastatic NSCLC without a targetable tumor mutation (1:41:13) Role of first-line immunotherapy in PD-L1-negative metastatic NSCLC (1:44:17) Implications of antibiotic use and autoimmune toxicity for checkpoint inhibitor efficacy (1:48:15) Faculty presentation: Dr Garon (1:53:41) Future Directions in the Management of Metastatic NSCLC Future directions in NSCLC: Tumor treating fields and datopotamab deruxtecan (2:04:14) Faculty presentation: Dr Leal (2:13:18) CME information and select publications

Featuring perspectives from Dr Christopher R Flowers, Ms Amy Goodrich, Ms Robin Klebig and Dr Matthew Lunning, including the following topics: Introduction (0:00) POLARIX: Polatuzumab Vedotin/R-CHP for Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (5:55) Polatuzumab Vedotin/Bendamustine/Rituximab and Selinexor for Relapsed Disease (24:28) CD19-Directed Antibody-Drug Conjugate Loncastuximab Tesirine (42:43) CD19-Directed Monoclonal Antibody Tafasitamab Combined with Lenalidomide (51:16) CD20 x CD3 Bispecific Antibodies (1:01:02) CAR (Chimeric Antigen Receptor) T-Cell Therapy (1:19:07) NCPD information and select publications

Featuring perspectives from Dr Brian Van Tine, including the following topics: Introduction (0:00) Case: A man in his mid 30s with metastatic recurrence of alveolar soft part sarcoma of the shoulder who received ipilimumab/nivolumab; imaging scan suspect for pseudoprogression — Nam Q Bui, MD (11:20) Case: A woman in her mid 30s with a 3-cm desmoid tumor who refuses treatment and is followed for 4 years, now with spontaneous tumor regression — Atif Hussein, MD, MMM (25:11) Case: A woman in her late teens with an unresectable, massive 14-cm desmoid tumor who receives sorafenib but has poor tolerance to treatment — Dr Hussein (32:35) Case: A woman in her early 40s with prior mastectomy for angiosarcoma of the right breast and recurrent disease who receives doxorubicin but develops a bleeding sigmoid mass and widespread metastases — Melanie B Thomas, MD (43:36) Case: A man in his mid 30s with a 5.5-cm leiomyosarcoma, 1 positive inguinal node and multiregimen-refractory disease — Dr Hussein (53:34) Case: A woman in her early 50s with past medical history of anemia, renal cell carcinoma and nephrectomy who is diagnosed with Grade I gastrointestinal stromal tumors, spindle cell type; c-KIT mutation — Dr Thomas(59:00) CME information and select publications

Featuring perspectives from Ms Ilene Galinsky, Dr Ruben A Mesa, Dr Daniel A Pollyea, Dr Richard M Stone and Dr Sara M Tinsley-Vance, including the following topics: Introduction (0:00) Overview of Myeloproliferative Neoplasms and Myelofibrosis (MF) — Impact of Ruxolitinib (5:28) New Agents in MF — Fedratinib, Momelotinib, Pacritinib (31:13) Myelodysplastic Syndromes — Management of Low- and High-Risk Disease (52:59) Overview of Acute Myeloid Leukemia (AML) (1:15:18) Targeted Therapy for AML (1:26:02) NCPD information and select publications

Featuring perspectives from Dr Neeraj Agarwal, Ms Kathy D Burns, Ms Susan K Roethke and Dr Sandy Srinivas, including the following topics: Introduction (0:00) Overview of Prostate Cancer (5:46) Intensification of Therapy for Localized Disease (35:19) Hormone-Sensitive Metastatic Disease (48:04) PARP Inhibitors (1:02:07) Radioligand Therapy (1:22:51) NCPD information and select publications

Featuring perspectives from Dr Michael J Overman, including the following topics: Introduction (0:00) Case: A woman in her mid 40s with microsatellite instability-high (MSI-H) colorectal adenocarcinoma metastatic to the brain receives pembrolizumab; KRAS G13D and somatic BRCA exon 11 mutations — Warren S Brenner, MD (16:27) Case: A woman in her late 50s with MSI-H Stage IIIB adenocarcinoma of the colon, BRAF V600E mutation — Eric H Lee, MD, PhD (23:20) Case: A woman in her early 70s with past medical history of diverticulitis and partial colectomy diagnosed with T1, microsatellite stable (MSS) cecal colon adenocarcinoma, minimum residual disease-negative after resection — Farshid Dayyani, MD, PhD (32:37) Case: A woman in her late 60s with past medical history of hypothyroidism has mass in right lung consistent with colorectal adenocarcinoma but no evidence of primary or other distant disease — Swati Vishwanathan, MD (42:58) Case: A woman in her mid 60s with multiregimen-relapsed RAS wild-type, HER2-positive metastatic rectal cancer, now receiving trastuzumab/tucatinib — Sunil Gandhi, MD (46:51) Case: A man in his mid 60s with MSS metastatic cecal adenocarcinoma and progressive disease on FOLFIRINOX/bevacizumab and capecitabine/bevacizumab maintenance — Dr Brenner (50:13) Case: A woman in her mid 60s with metastatic BRAF V600E-mutant colorectal adenocarcinoma, with circulating tumor DNA positivity after FOLFOX, heated intraperitoneal chemotherapy and colectomy/debulking surgery — Jeremy Lorber, MD (54:31) CME information and select publications

Featuring perspectives from Ms Courtney Arn, Dr David M O'Malley, Dr Richard T Penson and Ms Jaclyn Shaver, including the following topics: Introduction (0:00) Overview of Ovarian Cancer (4:50) Initial Management of Advanced Ovarian Cancer (26:41) Up-Front PARP Inhibitor Maintenance Therapy (33:10) Side Effects and Toxicities of PARP Inhibitors (37:07) Antibody-Drug Conjugates (1:02:13) Future Directions — Tumor Treating Fields (1:20:12) NCPD information and select publications

Featuring perspectives from Dr Joyce O'Shaughnessy, including the following topics: Introduction (0:00) HER2-Positive Metastatic Breast Cancer –– Professor Giuseppe Curigliano, MD, PhD (8:04) ASCO 2023 Preview (38:37) NCPD information and select publications

Featuring perspectives from Prof Sia Daneshmand, Dr Joshua J Meeks, Dr Matthew Milowsky and Prof J Alfred Witjes, moderated by Dr Arlene Siefker‑Radtke, including the following topics: Introduction (0:00) Current Role of Anti-PD-1/PD-L1 Antibodies in the Treatment of Non-Muscle-Invasive Bladder Cancer — Joshua J Meeks, MD, PhD (2:49) Contemporary Management of Muscle-Invasive Bladder Cancer — J Alfred Witjes, MD, PhD (26:30) Novel Strategies Under Investigation for Nonmetastatic Urothelial Bladder Cancer (UBC) — Sia Daneshmand, MD (48:02) Current and Future Up-Front Management of Metastatic UBC (mUBC) — Matthew Milowsky, MD (1:12:26) Selection and Sequencing of Therapy for Relapsed/Refractory mUBC — Arlene Siefker-Radtke, MD (1:33:25) CME information and select publications

Featuring perspectives from Dr Ahmed Omar Kaseb, Ms Blanca Ledezma, Dr Daneng Li and Ms Amanda K Wagner, including the following topics: Introduction (0:00) Overview of Hepatocellular Carcinoma (HCC) (3:37) First-Line Systemic Therapy for HCC (27:37) Therapy for Relapased HCC (41:43) Overview of Biliary Tract Cancers (54:10) First-Line Systemic Therapy for Biliary Tract Cancers (1:8:45) Targeted Treatment for Biliary Tract Cancers (1:11:25) NCPD information and select publications

Featuring perspectives from Dr John N Allan, Ms Jacqueline Broadway‑Duren, Ms Corinne Hoffman and Dr Adam S Kittai, including the following topics: Introduction (0:00) Overview of Chronic Lymphocytic Leukemia (CLL) (5:20) First-Line Therapy for CLL (32:06) Use of Venetoclax in Combination with an Anti-CD20 Antibody (49:16) Choice of BTK Inhibitor; BTK Inhibitor Toxicity (1:14:33) Noncovalent BTK Inhibitors (1:18:53) CAR T-Cell Therapy; Transformation (1:23:08) NCPD information and select publications

Featuring perspectives from Dr Himisha Beltran, Dr Stephen J Freedland, Dr Fred Saad and Dr Neal D Shore, moderated by Dr Matthew R Smith, including the following topics: Introduction (0:00) Management Approaches for Nonmetastatic Prostate Cancer — Dr Freedland (1:45) Optimizing the Care of Patients with Metastatic Hormone-Sensitive Prostate Cancer — Dr Saad (26:14) Therapeutic Considerations for Patients with Newly Diagnosed Metastatic CRPC (mCRPC) — Dr Shore (51:51) Contemporary Management of mCRPC in Patients Harboring a Homologous Recombination Repair Gene Alteration — Dr Smith (1:16:20) Current and Emerging Strategies in the Treatment of Recurrent mCRPC — Dr Beltran (1:36:47) CME information and select publications

Featuring perspectives from Dr Stephen V Liu, Ms Tara Plues, Ms Jillian Thompson and Dr Anne S Tsao, including the following topics: Introduction (0:00) Immunotherapy for Nonmetastatic and Metastatic Non-Small Cell Lung Cancer (NSCLC) (5:47) Future Directions — Tumor Treating Fields (37:30) Overview of Targeted Treatment for NSCLC (53:38) Targeted Treatment for NSCLC with an EGFR Mutation (1:10:48) EGFR Exon 20 Insertion Mutations (1:26:35) Targeted Treatment for NSCLC with a RET Fusion (1:37:40) Targeted Treatment for NSCLC with a KRAS G12C Mutation (1:46:45) NCPD information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Hepatobiliary Cancers — Facutly Presentation 2: Biliary Tract Cancers — Dr Richard S Finn CME information and select publications

Featuring perspectives from Drs Ghassan Abou‑Alfa and Richard S Finn, including the following topics: Introduction (0:00) Prologue: Last Week (2:33) Hepatocellular Carcinoma (4:37) Biliary Tract Cancers (35:20) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Hepatobiliary Cancers — Facutly Presentation 1: Hepatocellular Carcinoma — Dr Ghassan Abou-Alfa CME information and select publications

Featuring perspectives from Ms Jamie Carroll, Dr Virginia Kaklamani, Dr Joyce O'Shaughnessy and Mr Ronald Stein, including the following topics: Introduction (0:00) ER-Positive, HER2-Negative Localized Breast Cancer — Part 1 (7:12) ER-Positive, HER2-Negative Localized Breast Cancer —Part 2 (26:18) ER-Positive Metastatic Breast Cancer (37:16) Localized HER2-Positive Breast Cancer (49:27) HER2-Positive and HER2-Low Metastatic Breast Cancer — Part 1 (1:04:09) HER2-Positive and HER2-Low Metastatic Breast Cancer — Part 2 (1:27:00) PARP Inhibitors (1:32:21) Immune Checkpoint Inhibitors (1:43:32) CME information and select publications

Featuring perspectives from Ms Paula J Anastasia, Dr Michael J Birrer, Ms Jennifer Filipi and Dr Brian M Slomovitz, including the following topics: Introduction (0:00) Overview of Endometrial Cancer (9:50) Management of Microsatellite Instability-High Endometrial Cancer (23:40) Management of Microsatellite-Stable Endometrial Cancer (33:32) Clinical Trials in Endometrial Cancer (50:04) Systemic Therapy for Cervical Cancer — Immunotherapy (1:03:44) Antibody-Drug Conjugates for Cervical Cancer — Tisotumab Vedotin (1:16:01) NCPD information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Colorectal Cancer Faculty Presentation 2: Other Therapeutic Considerations in CRC — Dr Pashtoon M Kasi CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Colorectal Cancer Faculty Presentation 1: Targeted Therapy for Colorectal Cancer (CRC) — Dr Wells A Messersmith CME information and select publications

Featuring perspectives from Drs Pashtoon M Kasi and Wells A Messersmith, including the following topics: Introduction (0:00) Overview of Endometrial Cancer (9:50) Management of Microsatellite Instability-High Endometrial Cancer (23:40) Management of Microsatellite-Stable Endometrial Cancer (33:32) Clinical Trials in Endometrial Cancer (50:04) Systemic Therapy for Cervical Cancer — Immunotherapy (1:03:44) Antibody-Drug Conjugates for Cervical Cancer — Tisotumab Vedotin (1:16:01) CME information and select publications

Featuring perspectives from Drs Andrew J Armstrong and Rana R McKay, including the following topics: Introduction (0:00) Intensification of endocrine therapy: Emerging role in nonmetastatic disease; choice of androgen deprivation therapy (3:31) Management of castration-resistant M0 disease; PROTACs, CDK4/6 inhibitors and other new endocrine approaches (16:18) Hormone-sensitive metastatic disease — Choice of antiandrogen (26:48) Castration-resistant metastatic disease (37:06) Genomic evaluation; PARP inhibitors for metastatic disease (46:24) Ideal sequencing of PARP inhibitors; management of associated side effects (55:21) Biomarker testing; MSI-high disease; TKIs with immunotherapy; bispecific antibodies? (59:42) CME information and select publications

Oncology Today: Recent Research Advances in Prostate Cancer and the Clinical Implications – A 2023 Post-ASCO GU Activity — Faculty Presentation: Dr Daniel Petrylak Visit our website for more publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung Cancer — Faculty Presentation 2: Advances in the Care of Patients with Nonmetastatic NSCLC and Small Cell Lung Cancer — Dr Luis Paz-Ares CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung Cancer — Faculty Presentation 1: Management of Metastatic Non-Small Cell Lung Cancer (NSCLC) without an Actionable Mutation — Dr Heather Wakelee CME information and select publications

Featuring perspectives from Drs Luis Paz-Ares and Heather Wakelee, including the following topics: Introduction: Looking Back at Immuno-oncology Therapies (0:00) Metastatic Disease (7:46) Localized Non-Small Cell Lung Cancer (42:16) Small Cell Lung Cancer (59:48) CME information and select publications

Featuring perspectives from Dr Sara A Hurvitz, including the following topics: Introduction: Antibody-Drug Conjugates in Breast Cancer (0:00) Case: A premenopausal woman in her late 40s with 0.8-cm ER/PR-positive, HER2-negative invasive ductal carcinoma (IDC) with 2 positive nodes and an Oncotype DX® Recurrence Score® (RS) of 9 — Ranju Gupta, MD (13:59) Case: A premenopausal woman in her early 40s with 5-cm ER/PR-positive, HER2-negative Grade I IDC — Nick Leasure, MD (17:43) Case: A woman in her early 70s with ER/PR-positive, HER2-low (IHC 1+) metastatic IDC receiving T-DXd with mixed response — Gigi Chen, MD (38:38) Case: A woman in her late 40s with multicentric triple-negative breast cancer with a gBRCA1 mutation who receives treatment per KEYNOTE-522 and achieves a complete remission with neoadjuvant treatment — Zanetta S Lamar, MD (44:27) Case: A premenopausal woman in her early 50s with bilateral ER/PR-positive, HER2-negative, IDC with PALB2 mutation and multiple, bilateral positive nodes — William R Mitchell, MD (46:44) Case: A woman in her mid 30s who is 18 weeks pregnant and is diagnosed with ER/PR-positive, HER2-negative IDC and an Oncotype DX RS of 17 — Alan B Astrow, MD (50:48) Case: A woman in her late 40s with ER/PR-positive, HER2-negative metastatic breast cancer with NTRK mutation and CNS involvement who receives entrectinib — Rahul Gosain, MD (52:55) Case: A woman in her early 60s with ER/PR-positive, HER2-negative metaplastic breast cancer with an Oncotype DX RS of 51 who has received an adjuvant aromatase inhibitor for 16 years — Rajalaxmi McKenna, MD (56:04) CME information and select publications

Featuring perspectives from Drs Robert L Coleman, Matthew A Powell and Brian M Slomovitz, moderated by Dr Shannon N Westin, including the following topics: Immune Checkpoint Inhibitors for Patients with Advanced Microsatellite Instability (MSI)-High/Mismatch Repair (MMR)-Deficient Endometrial Cancer — Dr Powell Introduction (0:00) Case: A woman in her early 60s with MSI-high recurrent endometrioid adenocarcinoma of the uterus experiences progression after minimal response to carboplatin/paclitaxel — Lyndsay J Willmott, MD (2:25) Case: A woman in her early 50s with MSI-high metastatic endometrial adenocarcinoma after rapid, highly symptomatic progressive disease on paclitaxel/carboplatin — Kellie E Schneider, MD (8:21) Faculty presentation: Dr Powell (14:35) Immunotherapy-Based Strategies for Patients with MMR-Proficient (pMMR) Endometrial Cancer — Dr Coleman Case: A woman in her early 60s with a 10-cm right ovarian mass and right pelvic adenopathy; total abdominal hysterectomy with bilateral salpingo-oophorectomy and para-aortic lymph node dissection reveal microsatellite stable (MSS) carcinosarcoma of the endometrium with right ovary and pelvic lymph node involvement (R0); adjuvant paclitaxel/carboplatin administered — Thomas P Morrissey, MD (24:46) Case: A woman in her late 60s with Stage IB, Grade 1 endometrial cancer after hysterectomy/sentinel lymph node biopsy — Dana M Chase, MD (30:11) Faculty presentation: Dr Coleman (35:54) Diagnosis and Management of Adverse Events Associated with Immune Checkpoint Inhibitors Alone and in Combination for Endometrial Cancer — Dr Westin Case: A woman in her early 60s with a family history of breast cancer — Dr Morrissey (46:05) Case: A woman in her mid 70s who underwent hysterectomy, lymphadenectomy, omentectomy and 6 cycles of carboplatin/paclitaxel for a Stage IB MSS serous endometrial cancer; develops metastatic disease to the lungs 11 months later and is started on lenvatinib/pembrolizumab — Dr Chase (51:36) Faculty presentation: Dr Westin (57:09) Novel Investigational Agents and Strategies Under Evaluation for Patients with Endometrial Cancer — Dr Slomovitz Case: A woman in her early 70s with HER2-positive serous carcinoma of the uterus receives adjuvant carboplatin/paclitaxel and trastuzumab, now no evidence of disease and receiving maintenance trastuzumab — Dr Willmott (1:07:34) Case: A woman in her early 80s with MSI-high metastatic endometrial cancer who receives talazoparib on the TAPUR clinical trial after experiencing progressive disease on pembrolizumab after 4 cycles — John K Chan, MD (1:13:01) Faculty presentation: Dr Slomovitz (1:18:53) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Acute Myeloid Leukemia and Myelodysplastic Syndromes — Faculty Presentation 2: Myelodysplastic Syndromes — Dr Uma Borate, MD, MS CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Acute Myeloid Leukemia and Myelodysplastic Syndromes — Faculty Presentation 1: Acute Myeloid Leukemia — Prof Andrew H Wei CME information and select publications

Featuring perspectives from Dr Uma Borate and Prof Andrew Wei, including the following topics: Introduction (0:00) Acute Myeloid Leukemia (AML): Key Papers and Presentations (3:30) Myelodysplastic Syndromes (MDS): Key Papers and Presentations (36:32) CME information and select publications

Featuring perspectives from Dr Jacob Laubach, including the following topics: Evolution of first-line treatment for multiple myeloma (MM) (0:00) Perspectives on the future of bispecific antibody and chimeric antigen receptor (CAR) T-cell therapy for the management of MM (13:27) ASH 2022 updates on front-line management of MM for transplant-ineligible patients (18:35) ASH 2022 updates on the use of isatuximab-containing regimens for newly diagnosed and relapsed/refractory (R/R) MM (24:57) ASH 2022 updates on the clinical efficacy of CAR T-cell therapy for R/R MM; perspectives on the future of belantamab mafodotin (35:05) ASH 2022 updates on the efficacy and safety of teclistamab for R/R MM (46:33) Bispecific antibody therapy administration and patient education (52:41) ASH 2022 updates on investigational bispecific antibodies and other novel therapies for MM (1:00:17) CME information and select publications

Featuring perspectives from Dr Matthew Milowsky and Prof Thomas Powles, including the following topics: • Introduction (0:00) • Renal Cell Carcinoma (3:23) • Urothelial Bladder Cancer (35:05) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Renal Cell Carcinoma and Bladder Cancer — Faculty Presentation 2: Urothelial Bladder Cancer — Matthew Milowsky, MD CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Renal Cell Carcinoma and Bladder Cancer — Faculty Presentation 1: Kidney Cancer — Prof Thomas Powles CME information and select publications

Featuring perspectives from Drs Mansoor Raza Mirza, Amit M Oza and Richard T Penson, moderated by Dr Joyce F Liu, including the following topics: • Optimal Genomic Evaluation of and Targeted Therapies for Newly Diagnosed Advanced Ovarian Cancer — Dr Mirza o Introduction (0:00) o Case: A morbidly obese woman in her mid 40s who is a Jehovah's Witness with ovarian cancer and a germline BRCA2 mutation — Lyndsay J Willmott, MD (1:10) o Case: A woman in her early 50s with BRCA wild-type, homologous recombination repair deficiency (HRD)-negative Stage IV ovarian cancer, a large pleural effusion and ascites — Kellie E Schneider, MD (7:16) o Faculty presentation: Dr Mirza (13:51) • PARP Inhibitors for Relapsed/Refractory Ovarian Cancer — Dr Oza o Case: A woman in her mid 60s with recurrent BRCA wild-type ovarian cancer in ongoing and durable remission with paclitaxel/carboplatin followed by maintenance niraparib — John K Chan, MD (26:13) o Case: A woman in her early 50s with a germline BRCA2 mutation and recurrent platinum-sensitive ovarian cancer who received paclitaxel/carboplatin/bevacizumab and maintenance olaparib/bevacizumab — Thomas P Morrissey, MD (32:09) o Faculty presentation: Dr Oza (36:55) • Rationale for and Available Data with PARP Inhibitors in Combination with Other Anticancer Therapies for Advanced Ovarian Cancer — Dr Liu o Case: A woman in her early 20s with newly diagnosed Stage IV, low-grade serous carcinoma of the ovary with pleural effusions — Dana M Chase, MD (48:55) o Case: A woman in her late 40s with high-grade serous ovarian cancer who received neoadjuvant chemotherapy on the Phase III FIRST trial and undergoes R0 debulking surgery — Dr Schneider (52:51) o Faculty presentation: Dr Liu (57:39) • Novel Agents for the Treatment of Ovarian Cancer — Dr Penson o Case: A woman in her mid 60s with multiregimen-refractory metastatic ovarian cancer who receives paclitaxel/tumor treating fields on the INNOVATE-3 trial and develops dermatologic toxicity — Dr Chan (1:07:19) o Cases: A woman in her early 70s with multiple comorbidities and extensively treated recurrent, platinum-resistant BRCA wild-type, HRD-negative, PD-L1-positive, FR-alpha-mutant ovarian cancer and a woman in her mid 40s with a germline BRCA1 mutation and multiregimen-recurrent FR-alpha-mutant carcinomatosis — Dr Chase and Dr Willmott (1:11:00) o Faculty presentation: Dr Penson (1:18:20) CME information and select publications

Featuring an interview with Dr John Allan, including the following topics: • Update on key studies of acalabrutinib in the front-line setting (0:00) • Updated data from the GLOW study: First-line fixed-duration ibrutinib and venetoclax compared to chlorambucil and Obinutuzumab (21:11) • Treatment outcomes after achieving undetectable minimal residual disease (MRD) with first-line ibrutinib and venetoclax: Updated analysis of the CAPTIVATE trial (35:06) • Ibrutinib/venetoclax with MRD-driven duration of treatment: Updated analysis of the FLAIR trial (48:08) • Acalabrutinib with venetoclax and obinutuzumab for previously untreated chronic lymphocytic leukemia (CLL) in a population enriched for high-risk disease (50:49) • Risk factors to predict failure of therapy using fixed-duration venetoclax/obinutuzumab (53:22) • Updates on the ALPINE and BRUIN studies of zanubrutinib and pirtobrutinib, respectively, for relapsed/refractory CLL (56:15) • Emerging data with novel Bcl-2 inhibitors (1:11:26) • Evolving data with subcutaneous epcoritamab for patients with Richter's transformation and CLL (1:14:37) CME information and select publications

Featuring perspectives from Dr John Strickler, including the following topics: • Introduction: ASCO Guidelines for the Treatment of Metastatic Colorectal Cancer (0:00) • Case: A woman in her mid 70s with metastatic colon cancer — Sunil Gandhi, MD (11:14) • Case: A man in his late 70s with T3N0 MSS adenocarcinoma of the colon who is ctDNA-negative after colectomy and would like to avoid chemotherapy — Georges Azzi, MD (22:01) • Case: A woman in her early 80s with mismatch repair-proficient Stage IIIC high-risk adenocarcinoma of the colon with neuroendocrine features after adjuvant FOLFOX — Gigi Chen, MD (25:39) • Case: A man in his late 40s with a HER2-amplified ascending colon adenocarcinoma and liver metastases who undergoes perioperative FOLFOXIRI and liver resection — Swati Vishwanathan, MD (32:54) • Case: A man in his late 50s with metastatic adenocarcinoma of the colon and disease progression after multiple lines of chemotherapy — Priya Rudolph, MD, PhD (44:31) • Case: A man in his late 70s with metastatic rectal adenocarcinoma, high tumor mutational burden and multiple genetic alterations by liquid biopsy, including KRAS G12C — Shaachi Gupta, MD, MPH (48:31) • Case: A man in his early 60s with rectal cancer, synchronous liver metastases and lung oligometastases after perioperative FOLFOX and resection of the primary and liver metastases — Dr Gupta (55:36) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Prostate Cancer — Faculty Presentation 2: Evidence-Based Utilization of Other Therapeutic Approaches — A Oliver Sartor, MD CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Prostate Cancer — Faculty Presentation 1: Optimizing the Use of Hormonal Therapy in Prostate Cancer Management — Tanya B Dorff, MD CME information and select publications

Featuring perspectives from Drs Tanya Dorff and A Oliver Sartor, including the following topics: • Introduction (0:00) • Castration-Sensitive Prostate Cancer (5:26) • PARP Inhibitors in Castration-Resistant Disease (23:00) • Radiopharmaceuticals (39:46) CME information and select publications

Featuring perspectives from Drs Eric Lee, Neil Morganstein and Swati Vishwanathan, including the following topics: • Gastroesophageal Cancers — Zev Wainberg, MD, MSc o Introduction (0:00) o Systemic therapy considerations for HER2-negative localized gastroesophageal cancers (4:33) o First-line systemic therapy for metastatic esophageal or gastric cancer (10:05) o Zolbetuximab/chemotherapy as first-line treatment for HER2-negative, locally advanced unresectable or metastatic gastric and gastroesophageal junction cancers (16:19) o Repeat tissue biopsy versus circulating tumor DNA testing for HER2-positive GI cancers after disease progression on first-line therapy (20:59) o Trastuzumab deruxtecan as second-line therapy for HER2-positive gastric cancer; management of CNS disease (25:05) • Hepatobiliary Cancers — Lipika Goyal, MD, MPhil o Tissue biopsy for suspected hepatocellular carcinoma (HCC) (29:59) o Atezolizumab/bevacizumab versus durvalumab/tremelimumab as first-line therapy for HCC; disease etiology and response to treatment (33:34) o Liver-directed therapy in the era of effective novel systemic regimens (40:50) o First-line, single-agent immunotherapy for HCC (44:33) o Sequencing tyrosine kinase inhibitors for patients with HCC with and without contraindications to immunotherapy (47:46) o Survival benefit with durvalumab/gemcitabine/cisplatin for advanced biliary tract cancers (BTCs) in the TOPAZ-1 trial — A new standard? (51:25) o Spectrum of targetable genetic alterations in BTCs; novel FGFR2 inhibitors for cholangiocarcinoma (54:28) CME information and select publications

Oncology Today with Dr Neil Love: Special Edition — Current Management of Hepatobiliary Cancers — Dr Lipika Goyal Visit our website for more publications

Oncology Today with Dr Neil Love: Special Edition — Current Management of Hepatobiliary Cancers — Dr Zev Wainberg Visit our website for more publications

Featuring perspectives from Dr Sara Tolaney, including the following topics: • Introduction (00:00) • Case: A premenopausal woman in her early 30s with T1c N0 ER/PR-positive, HER2-negative, gBRCA2-mutant invasive ductal carcinoma (IDC) with an Oncotype DX® Recurrence Score® (RS) of 30 receives adjuvant chemotherapy followed by leuprolide/letrozole but wishes to discontinue treatment to attempt pregnancy — Alan B Astrow, MD (10:19) • Case: A woman in her late 30s with T2 N0 ER/PR-positive, HER2-negative IDC and RS of 35 has severe menopause after adjuvant TC, TAH/BSO and letrozole — Ranju Gupta, MD (22:18) • Case: A postmenopausal woman in her early 50s with bilateral ER-positive, HER2-negative breast cancer; RS on the left is low and on the right is 30 but the tumor is 4 millimeters — Zanetta S Lamar, MD (34:19) • Case: A premenopausal woman in her early 40s with a gBRCA2 mutation and Stage IIB ER/PR-positive, HER2-low (IHC 1+) IDC treated with adjuvant tamoxifen develops extensive metastases and receives ovarian function suppression, letrozole and palbociclib — Jeremy Lorber, MD (38:57) • Case: A woman in her early 70s with multiregimen-recurrent ER/PR-positive, HER2-low (IHC 1+) metastatic breast cancer receives T-DXd — Henna Malik, MD (54:25) • Case: A woman in her mid 40s with node-positive localized triple-negative breast cancer has residual disease after neoadjuvant pembrolizumab/chemotherapy and surgery — Laila Agrawal, MD (57:05) CME information and select publications

Featuring perspectives from Dr Matthew Galsky, Jonathan Rosenberg, and Dr Arlene Siefker-Radtke, moderated by Dr Elisabeth Heath, including the following topics: • Integrating Novel Treatment Strategies into the Management of Nonmetastatic Urothelial Bladder Cancer (UBC) — Dr Galsky o Introduction (00:00) o Case: A man in his late 70s with superficial transitional cell carcinoma of the bladder after bacillus Calmette-Guérin with positive ureteral washing — Sunil Gandhi, MD (2:38) o Cases: A man in his early 70s with high-grade papillary muscle-invasive bladder cancer with residual disease after neoadjuvant gemcitabine/cisplatin and cystectomy and a man in his early 80s with pT3N0 high-grade urothelial carcinoma after nephroureterectomy (GFR 40) — Ranju Gupta, MD and Swati Vishwanathan, MD (7:04) o Faculty presentation: Dr Galsky (13:16) • Current and Future Front-Line Treatment for Metastatic UBC (mUBC) — Dr Rosenberg o Cases: A man in his mid 70s with metastatic urothelial carcinoma now on maintenance avelumab after gemcitabine/cisplatin and a man in his early 50s with a history of ulcerative colitis diagnosed with metastatic urothelial carcinoma, including brain involvement — Paul Markowski, MD and Gigi Chen, MD) (23:33) o Case: A woman in her early 80s with unresectable localized urothelial carcinoma; PD-L1 CPS 5, TMB low — Spencer H Bachow, MD (30:54) o Faculty presentation: Dr Rosenberg (36:21) • Selection and Sequencing of Therapy for Relapsed/Refractory mUBC — Dr Siefker-Radtke o Case: A man in his mid 60s with metastatic bladder cancer and progressive disease on cisplatin/gemcitabine, now receiving sacituzumab govitecan — Priya Rudolph, MD, PhD (46:49) o Case: A man in his mid 60s with de novo metastatic urothelial bladder cancer now receiving pembrolizumab after gemcitabine/carboplatin (rapid progressive disease, FGFR3 mutation) — Yanjun Ma, MD (51:42) o Faculty presentation: Dr Siefker-Radtke (56:56) • Novel Investigational Agents and Strategies in the Treatment of mUBC — Dr Heath o Case: A man in his late 60s with metastatic urothelial carcinoma, PS 2 — Georges Azzi, MD (1:09:30) o Cases: A man in his mid 70s with metastatic mixed-histology (urothelial, small cell) bladder cancer who receives pembrolizumab and remains in remission 5 years later and a man in his early 50s with metastatic small cell carcinoma of the bladder who receives cisplatin, etoposide and durvalumab followed by maintenance durvalumab, now NED — Victoria Giffi, MD and Laurie Matt-Amaral, MD, MPH (1:13:48) o Faculty presentation: Dr Heath (1:19:43) CME information and select publications

Featuring perspectives from Dr Emmanuel Antonarakis, Prof Karim Fizazi, Dr Maha Hussain and Dr Matthew Smith, moderated by Dr Alan Bryce, including the following topics: • Management Approaches for Nonmetastatic Prostate Cancer — Dr Bryce o Introduction (00:00) o Case: A man in his early 70s with Gleason 8 prostate cancer after EBRT and leuprolide/enzalutamide, now receiving leuprolide/darolutamide with focal prostate uptake on PSMA PET — Priya Rudolph, MD, PhD (3:04) o Case: A man in his late 60s who underwent prostatectomy for Gleason 4 + 3 = 7 prostate cancer, now with increasing PSA levels — Nataliya Mar, MD (8:35) o Faculty presentation: Dr Bryce (15:12) • Optimizing the Care of Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) — Dr Hussain o Cases: A man in his early 70s with de novo mHSPC and a man in his mid 90s with de novo mHSPC — Georges Azzi, MD and Swati Vishwanathan, MD (23:29) o Case: A man in his early 70s with atrial fibrillation and rapid ventricular response who is diagnosed with de novo mHSPC (PSA 180,000 ng/mL) — Eric H Lee, MD, PhD (32:37) o Faculty presentation: Dr Hussain (37:34) • Current Therapeutic Options for Patients with Newly Diagnosed Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Dr Smith o Case: A man in his early 60s with de novo metastatic prostate cancer — Lai (Amber) Xu, MD, PhD (48:49) o Case: A man in his late 70s with mCRPC — Dr Rudolph (53:36) o Faculty presentation: Dr Smith (58:37) • Best Practice Management of mCRPC for Patients Harboring HRR Gene Alterations — Dr Antonarakis o Case: A man in his mid 70s with mCRPC with an ATM mutation who receives olaparib — Dr Vishwanathan (1:06:38) o Case: A man in his mid 70s with de novo mCRPC with a BRCA2 mutation who received multiple treatments and is now responding to olaparib but with transfusion-dependent neutropenia — Sunil Gandhi, MD (1:17:00) o Faculty presentation: Dr Antonarakis (1:21:30) • Current and Emerging Strategies for Patients with Recurrent mCRPC — Prof Fizazi o Case: A robust man in his mid 80s with mCRPC and rapid, symptomatic progressive disease through multiple treatments, now with extensive liver and bone metastases and small cell transformation — Vignesh Narayanan, MD (1:32:58) o Case: A man in his mid 70s with BRCA wild-type mHSPC who enrolls on a clinical trial of ADT/enzalutamide with or without a PD-1 inhibitor — David S Morris, MD (1:37:50) o Faculty presentation: Prof Fizazi (1:45:18) CME information and select publications

Featuring an interview with Drs Gottfried Konecny and Chirag Patel, including the following topics: • Tumor Treating Fields with Chirag B Patel, MD, PhD o Introduction (0:00) o Mechanism of action of tumor treating fields (5:53) o Tumor treating fields for glioblastoma multiforme (25:08) o Tumor treating fields for other tumor types (28:50) o Case presentations (34:10) • Updates on PARP Inhibitors in 2023 with Gottfried E Konecny, MD o PARP inhibitors as up-front maintenance therapy for ovarian cancer (37:15) o PARP inhibitors for recurrent ovarian cancer (44:34) CME information and select publications

Featuring perspectives from Dr Richard Finn, Dr Lipika Goyal and Prof Arndt Vogel, moderated by Dr Katie Kelley, including the following topics: • First-Line Treatment for Advanced Hepatocellular Carcinoma (HCC) — Dr Finn o Introduction (0:00) o Case: A man in his early 70s with newly diagnosed metastatic HCC receives atezolizumab/bevacizumab — Warren S Brenner, MD (2:27)) o Case: A woman in her late 50s with a history of hepatitis C and chronic kidney disease on dialysis with localized HCC after surgical resection; patient developed metastatic disease 10 months later — Liudmila N Schafer, MD (6:48) o Faculty presentation: Dr Finn (11:47) • Selection and Sequencing of Therapies for Relapsed/Refractory HCC — Dr Kelley o Case: A man in his mid 60s with metastatic HCC and a medical history of hepatitis C develops interstitial lung disease on atezolizumab/bevacizumab — Priya Rudolph, MD (21:48) o Cases: A man in his late 60s with post-transplant recurrence develops metastatic HCC and receives lenvatinib followed by cabozantinib followed by regorafenib and a man in his late 70s with metastatic HCC after treatment with atezolizumab/bevacizumab, lenvatinib and currently cabozantinib — Lionel A Kankeu Fonkoua, MD and Susmitha Apuri, MD (26:58) o Faculty presentation: Dr Kelley (35:56) • Current and Future Role of Immunotherapy in the Treatment of Advanced Biliary Tract Cancers (BTCs) — Prof Vogel o Case: A woman in her mid 70s with metastatic cholangiocarcinoma who received first-line gemcitabine/cisplatin with durvalumab — Dr Brenner (45:40) o Case: A man in his early 70s with localized cholangiocarcinoma deemed potentially resectable with tumor response — Jeremy Lorber, MD (50:23) o Faculty presentation: Dr Vogel (55:10) • Integration of Targeted Therapy into the Management of Advanced BTCs — Dr Goyal o Cases: A woman in her late 70s with intrahepatic cholangiocarcinoma considered unresectable — an FGFR2-KIAA1598 fusion was detected on NGS and a man in his early 60s with metastatic cholangiocarcinoma with severe muscle pain on pemigatinib — Dr Fonkoua and Joseph Martins, MD (1:06:18) o Cases: A man in his early 50s with recurrent metastatic cholangiocarcinoma with a BRAF V600E mutation treated with dabrafenib/trametinib and a woman in her mid 60s with cholangiocarcinoma with an IDH1 mutation receives ivosidenib — Farshid Dayyani, MD, PhD and Niyati A Nathwani, MD (1:12:26) o Faculty presentation: Dr Goyal (1:19:08) CME information and select publications

Proceedings from a symposium in partnership with NCOA and SCOS, featuring perspectives from Drs Ibiayi Dagogo-Jack and Stephen V Liu on recent advances and real-world implications in lung cancer. CME information and select publications